Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway

Cancer Lett. 2013 Jul 10;335(1):26-30. doi: 10.1016/j.canlet.2013.01.044. Epub 2013 Jan 31.


Aim of this study was to investigate phosphatidylethanolamine binding protein 1 (PEBP1) in GIST and its relations with MEK1/2 activation and ETV1 by immunohistochemistry. Loss of PEBP1 was found in 22/161 (13.7%) GIST, was associated with clinical risk factors and with a trend towards shorter disease free survival, but not with pMEK1/2 and ETV1 expression. So downregulation of PEBP1 does not activate the Ras-Raf-1-MEK1/2-ERK1/2 pathway by phosphorylation of MEK1/2 and does not influence ETV1 expression in GIST. Loss of PEBP1 associates with clinical risk factors, but since no significant influence on survival was found, further studies are required.

MeSH terms

  • Aged
  • DNA-Binding Proteins / metabolism
  • Disease-Free Survival
  • Down-Regulation*
  • Female
  • Gastrointestinal Neoplasms / enzymology*
  • Gastrointestinal Neoplasms / mortality
  • Gastrointestinal Stromal Tumors / enzymology*
  • Gastrointestinal Stromal Tumors / mortality
  • Humans
  • Kaplan-Meier Estimate
  • MAP Kinase Kinase Kinases / metabolism
  • MAP Kinase Signaling System*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Phosphatidylethanolamine Binding Protein / genetics*
  • Phosphatidylethanolamine Binding Protein / metabolism
  • Proto-Oncogene Proteins c-raf / metabolism
  • Risk Factors
  • Transcription Factors / metabolism


  • DNA-Binding Proteins
  • ETV1 protein, human
  • PEBP1 protein, human
  • Phosphatidylethanolamine Binding Protein
  • Transcription Factors
  • Proto-Oncogene Proteins c-raf
  • MAP Kinase Kinase Kinases